FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia

Article English OPEN
Peterlin, Pierre; Gaschet, Joëlle; Guillaume, Thierry; Garnier, Alice; Eveillard, Marion; Le Bourgeois, Amandine; Chérel, Michel; Debord, Camille; Le Bris, Yannick; Theisen, Olivier; Mahé, Béatrice; Dubruille, Viviane; Godon, Catherine; Robillard, Nelly; Wuilleme, Soraya; Touzeau, Cyrille; Gastinne, Thomas; Blin, Nicolas; Lok, Anne; Bonnet, Antoine; Le Gouill, Steven; Moreau, Philippe; Béné, Marie-C; Chevallier, Patrice;
(2019)
  • Publisher: Elsevier
  • Identifiers: doi: 10.1016/j.cyto.2019.04.015
  • Subject: Allogeneic stem cell transplantation | Acute Myeloid Leukemia | [SDV.CAN]Life Sciences [q-bio]/Cancer | Acute Lymphoblastic Leukemia | Fms-like tyrosine kinase 3 ligand
    mesheuropmc: hemic and lymphatic diseases | surgical procedures, operative

International audience; Objective: This study was designed to assess the impact on outcomes of early soluble Fms-like tyrosine kinase 3 ligand concentrations (sFLc) in patients receiving an allogeneic hematopoietic stem cell transplantation (allo-HSCT) for acute lymphob... View more
Share - Bookmark